DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

Advisory Commission on Childhood Vaccines; Notice of Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), notice is hereby given of the following meeting:

Name: Advisory Commission on Childhood Vaccines (ACCV)
Date and Time: June 14, 2012, 8:30 a.m. to 11:45 a.m. EDT.
Place: Parklawn Building (and via audio conference call), Conference Room 10–65, 5600 Fishers Lane, Rockville, MD 20857.
The ACCV will meet on Thursday, June 14 from 8:30 a.m. to 11:45 a.m. (EDT). The public can join the meeting via audio conference call by dialing 1–800–369–3104 on June 14 and providing the following information.

Leader’s Name: Dr. Geoffrey Evans.
Password: ACCV.

Agenda: The agenda items for the June meeting will include, but are not limited to: updates from the Division of Vaccine Injury Compensation (DVIC), Department of Justice (DOJ), National Vaccine Program Office (NVPO), Immunization Safety Office (Centers for Disease Control and Prevention), National Institute of Allergy and Infectious Diseases (National Institutes of Health) and Center for Biologics, Evaluation and Research (Food and Drug Administration). A draft agenda and additional meeting materials will be posted on the ACCV Web site (http://www.hrsa.gov/vaccinecompensation/accv.htm) prior to the meeting. Agenda items are subject to change as priorities dictate.

Public Comment: Persons interested in attending the meeting in person or providing an oral presentation should submit a written request, along with a copy of their presentation to: Annie Herzog, DVIC, Healthcare Systems Bureau (HSB), Health Resources and Services Administration (HRSA), Room 10C–26, 5600 Fishers Lane, Rockville, Maryland 20857 or email: aherzog@hrsa.gov. Requests should contain the name, address, telephone number, email address, and any business or professional affiliation of the person desiring to make an oral presentation. Groups having similar interests are requested to combine their comments and present them through a single representative. The allocation of time may be adjusted to accommodate the level of expressed interest. DVIC will notify each presenter of their assigned presentation time by email, mail, or telephone. Persons who do not file an advance request for a presentation, but desire to make an oral statement, may announce it at the time of the public comment period. Public participation and ability to comment will be limited to space and time as it permits.

For Further Information Contact: Anyone requiring information regarding the ACCV should contact: Annie Herzog, DVIC, HSB, HRSA, Room 11C–26, 5600 Fishers Lane, Rockville, MD 20857; telephone (301) 443–6593; email: aherzog@hrsa.gov.


Reva Harris,
Acting Director, Division of Policy and Information Coordination.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Biomedical Imaging and Bioengineering; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the Recombinant DNA Advisory Committee.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

Name of Committee: Recombinant DNA Advisory Committee.
Date: June 19, 2012.

Time: 9:00 a.m. to 3:30 p.m.

Agenda: The NIH Recombinant DNA Advisory Committee (RAC) will discuss selected human gene transfer protocols. Please view the meeting agenda at http://oba.od.nih.gov/rdna_rac/rac_meetings.html for more information.

Place: National Institutes of Health, Building 31C, 9090 Rockville Pike, 6th Floor Conference Room, Rockville, MD 20892.

Contact Person: Chezelle George, Office of Biotechnology Activities, Office of Science Policy/OD, National Institutes of Health, 6705 Rockledge Drive, Room 750, Bethesda, MD 20892, 301–496–9838, georgec@od.nih.gov.

OBA will again offer those members of the public viewing the meeting via webcast (see OBA Meetings Page available at http://oba.od.nih.gov/rdna_rac/rac_meetings.html) the opportunity to submit comments during the public comment periods. Individuals wishing to submit comments should use the comment form, which will accommodate comments up to 1500 characters, and will be available on the OBA Web site during the meeting (see OBA Meetings Page). Please limit your comments to a statement that can be read in one to two minutes. Please include your name and affiliation with your comment. Only comments submitted through the OBA Web site will be read.

OBA will read comments into the record during the public comment periods as stated on the agenda. It is not unusual for the meeting to run ahead or behind schedule due to changes in the time needed to review a protocol. It is advisable to monitor the webcast to determine when public comments will be read. Each public comment period follows a specific discussion item. OBA will
read comments that are related to the protocol under discussion at that time. General comments unrelated to the protocol or presentation under discussion at that time. General comments unrelated to a specific agenda item will be read at the end of the meeting, time permitting. Comments submitted by email through the OBA Web site will follow any comments by individuals attending the meeting. Comments will be read in the order received and your name and affiliation will be read with the comments. Please note OBA may not be able to read every comment received in the time allotted for public comment. Comments not read will become part of the public record.

In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver’s license, or passport) and to state the purpose of their visit. Information is also available on the Institute’s/Center’s home page: http://oba.od.nih.gov/rdna/rdna.html, where an agenda and any additional information for the meeting will be posted when available.

OMB’s “Mandatory Information Requirements for Federal Assistance Program Announcements” (45 FR 39592, June 11, 1980) requires a statement concerning the official government programs contained in the Catalog of Federal Domestic Assistance. Normally NIH lists in its announcements the number and title of affected individual programs for the guidance of the public. Because the guidance in this notice covers virtually every NIH and Federal research program in which DNA recombinant molecule techniques could be used, it has been determined not to be cost effective or in the public interest to attempt to list these programs. Such a list would likely require several additional pages. In addition, NIH could not be certain that every Federal program would be included as many Federal agencies, as well as private organizations, both national and international, have elected to follow the NIH Guidelines. In lieu of the individual program listing, NIH invites readers to direct questions to the information address above about whether individual programs listed in the Catalog of Federal Domestic Assistance are affected.


Name of Committee: Center for Scientific Review Special Emphasis Panel: Small Business: Sensory Technologies.

Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR12–054:

Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR09–221: Innovations in Biomedical Computational Science and Technology Initiative.

Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR09–221: Innovations in Biomedical Computational Science and Technology Initiative.

Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR09–221: Innovations in Biomedical Computational Science and Technology Initiative.

Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR09–221: Innovations in Biomedical Computational Science and Technology Initiative.

Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR09–221: Innovations in Biomedical Computational Science and Technology Initiative.

Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR09–221: Innovations in Biomedical Computational Science and Technology Initiative.

Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR09–221: Innovations in Biomedical Computational Science and Technology Initiative.

Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR09–221: Innovations in Biomedical Computational Science and Technology Initiative.

Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR09–221: Innovations in Biomedical Computational Science and Technology Initiative.

Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR09–221: Innovations in Biomedical Computational Science and Technology Initiative.

Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR09–221: Innovations in Biomedical Computational Science and Technology Initiative.

Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR09–221: Innovations in Biomedical Computational Science and Technology Initiative.

Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR09–221: Innovations in Biomedical Computational Science and Technology Initiative.